For this reason the company would be irresponsible if they did not raise enough monies now to clear the First Eye Loan and a some monies to start new trials.

Not doing so seems to say they are extremely confident that the RVX-208 will complete the Primary endpoint with success.

Perhaps they have the Number of Accumulated Patient Years and with that feel that the trial is doing what they are hopng for.

I guess we will have a better idea when they announce the next financing.